• Net Sales: $196.6 million, representing a 7% year-over-year growth on a constant currency basis.
• Adjusted EBITDA: $19.2 million, with a margin expansion of approximately 250 basis points.
• Free Cash Flow: Positive $5.9 million for the quarter.
• Bone Growth Therapy Revenue: Grew 9% to $57.9 million, with 13% growth in the fracture market.
• US Spine Fixation Revenue: Increased by 18%, more than triple the market growth rate.
• Global Spinal Implants, Biologics, and Enabling Technologies Revenue: $108.2 million, with 7% year-over-year growth.
• US Orthopedics Revenue: Grew 15%, contributing to a 3% growth in the global orthopedics business.
• Total Cash Balance: Approximately $32.6 million, including restricted cash.
• Full-Year 2024 Guidance: Net sales of $795 million to $800 million, with non-GAAP adjusted EBITDA of $64 million to $69 million.

• Warning! GuruFocus has detected 8 Warning Signs with OFIX.

Release Date: November 07, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Orthofix Medical Inc (NASDAQ:OFIX) reported a strong third quarter with net sales of $196.6 million, representing a 7% year-over-year growth on a constant currency basis.
• The company achieved record performances in its USA orthopedics business and the number of 7D earnouts agreements, indicating strong market demand.
• Orthofix Medical Inc (NASDAQ:OFIX) saw an 18% growth in US spine fixation, more than triple the market rate, driven by new product introductions and experienced distribution partners.
• The Bone Growth Therapy (BGT) segment grew 9% overall, with a 13% increase in the fracture market, highlighting successful cross-selling strategies.
• The company successfully completed a new $275 million financing to replace its existing credit facility, optimizing its capital structure for long-term growth.

Negative Points

• The international orthopedics business declined by 2% compared to the previous year, indicating challenges in global market penetration.
• US biologics business growth was below the overall market due to distributor transformation, impacting performance.
• Orthofix Medical Inc (NASDAQ:OFIX) anticipates moderation in BGT growth rates as they anniversary gains from previous quarters.
• The company faces potential risks from market growth fluctuations and external factors like IV fluid shortages and hurricane impacts, which are not accounted for in their guidance.
• Orthofix Medical Inc (NASDAQ:OFIX) is still in the early stages of building its position in the fracture market, which presents both opportunities and challenges.

Q & A Highlights

Q: What are the key metrics in the long-range plan that might be challenging to achieve by 2027? A: Julie Andrews, CFO, mentioned that while they are confident in hitting their targets, market growth will be a key factor to monitor. They are confident in delivering mid-teens adjusted EBITDA and positive free cash flow.

Q: Is the mid-teens EBITDA target by 2027 a milestone or a final goal? A: Julie Andrews, CFO, clarified that it is a milestone, not a final goal. The company does not see the mid-teens number as a stopping point, despite the structural changes since Orthofix's historical 20% EBITDA.

Q: How is Orthofix planning to sustain above-market growth rates in each segment through the long-range plan? A: Julie Andrews, CFO, highlighted opportunities in the US spine market and orthopedics, where they have a small market share but a strong portfolio. Massimo Calafiore, CEO, added that their platform, including 7D technology, positions them well for above-market growth.

Q: What are the drivers for adjusted EBITDA margin expansion through 2027? A: Julie Andrews, CFO, pointed to gross margin expansion opportunities, merger-related synergies, and scale on G&A costs as key drivers. They aim to leverage higher revenue for improved EBITDA margins.

Q: Who are the main customers for the 7D Flash Navigation System, and how is it being used? A: Massimo Calafiore, CEO, explained that the main customers are in the spine market, using 7D primarily for open surgeries, which still represent 80% of the market. They are also developing MIS solutions to expand into ASCs.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.